These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 32803850)

  • 1. Extremely high birth prevalence of sickle cell disease in rural Tanzania.
    Eastburg L; Peckham A; Kawira E; Chirangi B; Adler D; Akungo BD; Smart LR; Ambrose EE
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28620. PubMed ID: 32803850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test.
    Steele C; Sinski A; Asibey J; Hardy-Dessources MD; Elana G; Brennan C; Odame I; Hoppe C; Geisberg M; Serrao E; Quinn CT
    Am J Hematol; 2019 Jan; 94(1):39-45. PubMed ID: 30290004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newborn Screening for Sickle Cell Disease Using Point-of-Care Testing in Low-Income Setting.
    Alvarez OA; Hustace T; Voltaire M; Mantero A; Liberus U; Saint Fleur R
    Pediatrics; 2019 Oct; 144(4):. PubMed ID: 31530717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-Care Newborn Screening for Sickle Cell Disease at Selected Health Facilities in the Gambia.
    Adegoke SA; Makalo L; Sallah A; Saine H; Joof S; Conteh A; Bah R; Camara Jammeh AF; Bass M; Jallow M; Nnodu OE
    Hemoglobin; 2024 May; 48(3):169-174. PubMed ID: 38980121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of birth prevalence of sickle cell disease using point of care test HemotypeSC™ at Rundu Hospital, Namibia.
    Mano RM; Kuona P; Misihairabgwi JM
    BMC Pediatr; 2024 May; 24(1):323. PubMed ID: 38730340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening.
    Kunz JB; Awad S; Happich M; Muckenthaler L; Lindner M; Gramer G; Okun JG; Hoffmann GF; Bruckner T; Muckenthaler MU; Kulozik AE
    Ann Hematol; 2016 Feb; 95(3):397-402. PubMed ID: 26658910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newborn screening for sickle cell disease: an innovative pilot program to improve child survival in Dar es Salaam, Tanzania.
    Nkya S; Mtei L; Soka D; Mdai V; Mwakale PB; Mrosso P; Mchoropa I; Rwezaula S; Azayo M; Ulenga N; Ngido M; Cox SE; D'Mello BS; Masanja H; Kabadi GS; Mbuya F; Mmbando B; Daniel Y; Streetly A; Killewo J; Tluway F; Lyimo M; Makani J
    Int Health; 2019 Nov; 11(6):589-595. PubMed ID: 31145786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of point of care tests for newborn screening for sickle cell disease: Evaluation of HemotypeSC™ and sickle SCAN® in Tanzania.
    Christopher H; Josephat E; Kaywanga F; Saul S; Mshana I; Kunambi P; Nasser A; Chamba C; Makani J; Nkya S
    Int J Lab Hematol; 2022 Oct; 44(5):959-965. PubMed ID: 35775883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn Screening and Clinical Profile of Children With Sickle Cell Disease in a Tribal Area of Gujarat.
    Dave K; Desai S; Italia Y; Mukherjee MB; Mehta P; Desai G
    Indian Pediatr; 2022 Mar; 59(3):230-233. PubMed ID: 35014619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study.
    Nnodu OE; Sopekan A; Nnebe-Agumadu U; Ohiaeri C; Adeniran A; Shedul G; Isa HA; Owolabi O; Chianumba RI; Tanko Y; Iyobosa JH; Adekile AD; Olopade OI; Piel FB
    Lancet Haematol; 2020 Jul; 7(7):e534-e540. PubMed ID: 32589979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014-2019.
    Hernandez AG; Kiyaga C; Howard TA; Ssewanyana I; Ndeezi G; Aceng JR; Ware RE
    Trop Med Int Health; 2021 Jan; 26(1):23-32. PubMed ID: 33151598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Sickle Cell Trait and Reliability of Self-Reported Status among Expectant Parents in Nigeria: Implications for Targeted Newborn Screening.
    Burnham-Marusich AR; Ezeanolue CO; Obiefune MC; Yang W; Osuji A; Ogidi AG; Hunt AT; Patel D; Ezeanolue EE
    Public Health Genomics; 2016; 19(5):298-306. PubMed ID: 27614873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community based screening for sickle haemoglobin among pregnant women in Benue State, Nigeria: I-Care-to-Know, a Healthy Beginning Initiative.
    Ezenwosu OU; Itanyi IU; Nnodu OE; Ogidi AG; Mgbeahurike F; Ezeanolue EE
    BMC Pregnancy Childbirth; 2021 Jul; 21(1):498. PubMed ID: 34238241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action.
    Colombatti R; Martella M; Cattaneo L; Viola G; Cappellari A; Bergamo C; Azzena S; Schiavon S; Baraldi E; Dalla Barba B; Trafojer U; Corti P; Uggeri M; Tagliabue PE; Zorloni C; Bracchi M; Biondi A; Basso G; Masera N; Sainati L
    Pediatr Blood Cancer; 2019 May; 66(5):e27657. PubMed ID: 30724025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance for sickle cell disease, United Republic of Tanzania.
    Ambrose EE; Smart LR; Charles M; Hernandez AG; Latham T; Hokororo A; Beyanga M; Howard TA; Kamugisha E; McElhinney KE; Tebuka E; Ware RE
    Bull World Health Organ; 2020 Dec; 98(12):859-868. PubMed ID: 33293746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal Screening for Sickle Cell Disease in Western Andalusia: Results and Lessons Learnt after 3 Years of Implementation.
    Núñez-Jurado D; Payán-Pernía S; Álvarez-Ríos AI; Jiménez-Jambrina M; Concepcion Pérez-De-Soto I; José Palma-Vallellano A; Zapata-Bautista R; Carlos Hernández-Castellet J; Paz Garrastazul-Sánchez M; Arqueros-Martínez V; Urbano-Ramos MDM; Abdelkader-Maanan M; Raúl García-Lozano J; Delgado-Pecellín C
    Am J Perinatol; 2024 May; 41(S 01):e893-e900. PubMed ID: 36580977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and factors associated with renal dysfunction among children with sickle cell disease attending the sickle cell disease clinic at a tertiary hospital in Northwestern Tanzania.
    Kimaro FD; Jumanne S; Sindato EM; Kayange N; Chami N
    PLoS One; 2019; 14(6):e0218024. PubMed ID: 31211789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology.
    Green NS; Zapfel A; Nnodu OE; Franklin P; Tubman VN; Chirande L; Kiyaga C; Chunda-Liyoka C; Awuonda B; Ohene-Frempong K; Inusa BPD; Ware RE; Odame I; Ambrose EE; Dogara LG; Oron AP; Willett C; Thompson AA; Berliner N; Coetzer TL; Novelli EM
    Blood Adv; 2022 Dec; 6(24):6187-6197. PubMed ID: 36264096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High birth prevalence of sickle cell disease in Northwestern Tanzania.
    Ambrose EE; Makani J; Chami N; Masoza T; Kabyemera R; Peck RN; Kamugisha E; Manjurano A; Kayange N; Smart LR
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28766840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newborn blood spot screening for sickle cell disease by using tandem mass spectrometry: implementation of a protocol to identify only the disease states of sickle cell disease.
    Moat SJ; Rees D; King L; Ifederu A; Harvey K; Hall K; Lloyd G; Morrell C; Hillier S
    Clin Chem; 2014 Feb; 60(2):373-80. PubMed ID: 24158758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.